A Phase 1/1b Open-Label Dose-Escalation and Dose-Optimization Study of Bcl-2 Inhibitor BGB 21447 in Patients With Mature B Cell Malignancies
BGB-21447-101
Phase 1 other active
Quick answer
A Phase 1/1b Open-Label Dose-Escalation and Dose-Optimization Study of Bcl-2 Inhibitor BGB 21447 in Patients With Mature B Cell Malignancies for mature B-Cell malignancies is a Phase 1 program (other) at BeiGene Ireland Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- BeiGene Ireland Ltd
- Indication
- mature B-Cell malignancies
- Phase
- Phase 1
- Modality
- other
- Status
- active